Cargando…
Aryl methylene ketones and fluorinated methylene ketones as reversible inhibitors for severe acute respiratory syndrome (SARS) 3C-like proteinase
The severe acute respiratory syndrome (SARS) virus depends on a chymotrypsin-like cysteine proteinase (3CL(pro)) to process the translated polyproteins to functional viral proteins. This enzyme is a target for the design of potential anti-SARS drugs. A series of ketones and corresponding mono- and d...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112044/ https://www.ncbi.nlm.nih.gov/pubmed/18295820 http://dx.doi.org/10.1016/j.bioorg.2008.01.001 |
_version_ | 1783513405373546496 |
---|---|
author | Zhang, Jianmin Huitema, Carly Niu, Chunying Yin, Jiang James, Michael N.G. Eltis, Lindsay D. Vederas, John C. |
author_facet | Zhang, Jianmin Huitema, Carly Niu, Chunying Yin, Jiang James, Michael N.G. Eltis, Lindsay D. Vederas, John C. |
author_sort | Zhang, Jianmin |
collection | PubMed |
description | The severe acute respiratory syndrome (SARS) virus depends on a chymotrypsin-like cysteine proteinase (3CL(pro)) to process the translated polyproteins to functional viral proteins. This enzyme is a target for the design of potential anti-SARS drugs. A series of ketones and corresponding mono- and di-fluoro ketones having two or three aromatic rings were synthesized as possible reversible inhibitors of SARS 3CL(pro). The design was based on previously established potent inhibition of the enzyme by oxa analogues (esters), which also act as substrates. Structure–activity relationships and modeling studies indicate that three aromatic rings, including a 5-bromopyridin-3-yl moiety, are key features for good inhibition of SARS 3CL(pro). Compound 11d, 2-(5-bromopyridin-3-yl)-1-(5-(4-chlorophenyl)furan-2-yl)ethanone and its α-monofluorinated analogue 12d, gave the best reversible inhibition with IC(50) values of 13 μM and 28 μM, respectively. In contrast to inhibitors having two aromatic rings, α-fluorination of compounds with three rings unexpectedly decreased the inhibitory activity. |
format | Online Article Text |
id | pubmed-7112044 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71120442020-04-02 Aryl methylene ketones and fluorinated methylene ketones as reversible inhibitors for severe acute respiratory syndrome (SARS) 3C-like proteinase Zhang, Jianmin Huitema, Carly Niu, Chunying Yin, Jiang James, Michael N.G. Eltis, Lindsay D. Vederas, John C. Bioorg Chem Article The severe acute respiratory syndrome (SARS) virus depends on a chymotrypsin-like cysteine proteinase (3CL(pro)) to process the translated polyproteins to functional viral proteins. This enzyme is a target for the design of potential anti-SARS drugs. A series of ketones and corresponding mono- and di-fluoro ketones having two or three aromatic rings were synthesized as possible reversible inhibitors of SARS 3CL(pro). The design was based on previously established potent inhibition of the enzyme by oxa analogues (esters), which also act as substrates. Structure–activity relationships and modeling studies indicate that three aromatic rings, including a 5-bromopyridin-3-yl moiety, are key features for good inhibition of SARS 3CL(pro). Compound 11d, 2-(5-bromopyridin-3-yl)-1-(5-(4-chlorophenyl)furan-2-yl)ethanone and its α-monofluorinated analogue 12d, gave the best reversible inhibition with IC(50) values of 13 μM and 28 μM, respectively. In contrast to inhibitors having two aromatic rings, α-fluorination of compounds with three rings unexpectedly decreased the inhibitory activity. Elsevier Inc. 2008-10 2008-03-04 /pmc/articles/PMC7112044/ /pubmed/18295820 http://dx.doi.org/10.1016/j.bioorg.2008.01.001 Text en Copyright © 2008 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Zhang, Jianmin Huitema, Carly Niu, Chunying Yin, Jiang James, Michael N.G. Eltis, Lindsay D. Vederas, John C. Aryl methylene ketones and fluorinated methylene ketones as reversible inhibitors for severe acute respiratory syndrome (SARS) 3C-like proteinase |
title | Aryl methylene ketones and fluorinated methylene ketones as reversible inhibitors for severe acute respiratory syndrome (SARS) 3C-like proteinase |
title_full | Aryl methylene ketones and fluorinated methylene ketones as reversible inhibitors for severe acute respiratory syndrome (SARS) 3C-like proteinase |
title_fullStr | Aryl methylene ketones and fluorinated methylene ketones as reversible inhibitors for severe acute respiratory syndrome (SARS) 3C-like proteinase |
title_full_unstemmed | Aryl methylene ketones and fluorinated methylene ketones as reversible inhibitors for severe acute respiratory syndrome (SARS) 3C-like proteinase |
title_short | Aryl methylene ketones and fluorinated methylene ketones as reversible inhibitors for severe acute respiratory syndrome (SARS) 3C-like proteinase |
title_sort | aryl methylene ketones and fluorinated methylene ketones as reversible inhibitors for severe acute respiratory syndrome (sars) 3c-like proteinase |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112044/ https://www.ncbi.nlm.nih.gov/pubmed/18295820 http://dx.doi.org/10.1016/j.bioorg.2008.01.001 |
work_keys_str_mv | AT zhangjianmin arylmethyleneketonesandfluorinatedmethyleneketonesasreversibleinhibitorsforsevereacuterespiratorysyndromesars3clikeproteinase AT huitemacarly arylmethyleneketonesandfluorinatedmethyleneketonesasreversibleinhibitorsforsevereacuterespiratorysyndromesars3clikeproteinase AT niuchunying arylmethyleneketonesandfluorinatedmethyleneketonesasreversibleinhibitorsforsevereacuterespiratorysyndromesars3clikeproteinase AT yinjiang arylmethyleneketonesandfluorinatedmethyleneketonesasreversibleinhibitorsforsevereacuterespiratorysyndromesars3clikeproteinase AT jamesmichaelng arylmethyleneketonesandfluorinatedmethyleneketonesasreversibleinhibitorsforsevereacuterespiratorysyndromesars3clikeproteinase AT eltislindsayd arylmethyleneketonesandfluorinatedmethyleneketonesasreversibleinhibitorsforsevereacuterespiratorysyndromesars3clikeproteinase AT vederasjohnc arylmethyleneketonesandfluorinatedmethyleneketonesasreversibleinhibitorsforsevereacuterespiratorysyndromesars3clikeproteinase |